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Abstract
Purpose of Review Beta-cell replacement is the best therapeutic option for patients with type 1 diabetes. Because of donor
scarcity, more extended criteria donors are used for transplantation. Donation after circulatory death donors (DCD) are not
commonly used for pancreas transplantation, because of the supposed higher risk of complications. This review gives an
overview on the pathophysiology, risk factors, and outcome in DCD transplantation and discusses different preservation
methods.
Recent Findings Studies on outcomes of DCD pancreata show similar results compared with those of donation after brain death
(DBD), when accumulation of other risk factors is avoided. Hypothermic machine perfusion is shown to be a safe method to
improve graft viability in experimental settings.
Summary DCD should not be the sole reason to decline a pancreas for transplantation. Adequate donor selection and improved
preservation techniques can lead to enhanced pancreas utilization and outcome.
Keywords DCD . Pancreas transplantation . Preservation .Machine perfusion
Introduction
In a select group of patients with type 1 diabetes mellitus
(DM) with severe complications, beta-cell replacement by ei-
ther pancreas or islets of Langerhans transplantation is the
treatment of choice, leading to restoration of normoglycemia,
reduction of long-term diabetes complications, and improved
quality of life [1, 2]. Results of pancreas transplantation have
improved in the last decades by optimization of surgical tech-
niques and immunosuppressive regiments [3, 4]. Since
pancreas transplantation is not a direct life-saving operation,
strict donor selection criteria are used when accepting a pan-
creas [2, 5]. Despite a growing incidence in type 1 DMworld-
wide, pancreas transplant numbers in the USA and
Eurotransplant region are decreasing, whereas numbers in
the UK remain practically stable [6]. The main reasons for this
are the lack of good-quality donor grafts and improvement in
DM treatment, even though pancreas transplantation leads to
more stable glycated hemoglobin (HbA1c) levels compared
with strict insulin regimens [7], and long-term results of si-
multaneous pancreas-kidney (SPK) transplantation demon-
strate a clear survival benefit as compared with patients who
remain on the waiting list [8]. Forced by donor shortage, now-
adays, more extended criteria donors (ECD) are used for trans-
plantation, i.e., donation after brain death donation after brain
death donors (DBD) of higher age and BMI, or donation after
circulatory death donors (DCD). Most transplanted pancreata
originate from DCD Class III (controlled) and less frequently
from Class IV (uncontrolled controlled) donors. Maastricht
Class I and II (uncontrolled) donors generally are not used
for pancreas transplantation [9]. Clinicians are often reluctant
to accept DCD for pancreas transplantation given the higher
risk of graft pancreatitis and thrombosis, leading to potentially
devastating complications [2]. The aim of this review is to
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give an overview on the pathophysiology, risk factors, and
outcome in DCD transplantation, to provide tools in selecting
suitable pancreas donors and to describe ways to optimize
these organs by different preservation methods to safely in-
crease the pancreas donor pool.
Donor Selection
It has been generally assumed that the pancreas is much more
vulnerable to injury than other abdominal organs [10•].
Therefore, strict donor selection criteria are used in pancreas
transplantation, resulting in much higher discard rates of do-
nor pancreata for transplantation when compared with other
abdominal organs [5]. As a tool to assess suitable pancreas
donors, the Pre-Procurement-Pancreas-Suitability-Score (P-
PASS) was introduced in 2008 by the Eurotransplant
Pancreas Advisory Committee. This scoring system was
based on pancreas acceptance rate and includes nine donor
parameters: age, body mass index (BMI), duration of inten-
sive care unit (ICU) stay, cardiac arrest, serum sodium, amy-
lase, lipase, and catecholamine dose. A range and point weight
for each variable was defined based on clinical expertise and
known literature, whereby the variables age and BMI were
given twofold higher impact than the other variables.
Retrospective analysis of more than 3000 reported pancreas
donors identified a P-PASS of 17 as a significant cutoff point
(p = 0.001) for pancreas acceptance: pancreata from donors
with P-PASS > 17 were three times more likely to be
discarded [11]. Subsequently, Eurotransplant recommends
that all donors with a P-PASS < 17 have to be considered for
pancreas donation [12]. A drawback of the P-PASS is a lack of
data on patient and graft survival in the initial report, as it was
only based on the pancreas acceptance rate. Also, DCD is not
included in the scoring system, while nowadays there is a shift
towards increasing numbers of DCD [13].
In 2010, the pancreas donor risk index (PDRI) was designed
using data from the organ procurement and transplantation net-
work (OPTN) with the aim to identify factors associated with
pancreas graft survival after 1 year [14]. This index includes
donor factors as well as transplant factors: donor gender, age,
race (black/Asian), BMI, height, cause of death, serum creati-
nine, DCD status, preservation time, and type of transplantation.
PDRIwas derived from a large data set and provides an index for
direct comparison of a potential donor with a “standard donor.”
This model can help in the decision to accept a pancreas and to
compare the results after transplantation.
Several studies have tried to compare and validate the scor-
ing systems in retrospective analyses, usually resulting in con-
flicting outcomes. In a retrospective study using an
Eurotransplant cohort from 2004 to 2014 investigating the
predictive value of both indices on pancreas allocation,
PDRI was proven more useful than P-PASS to predict pancre-
as acceptance. However, the authors suggest that potential
pancreas donors should never be rejected exclusively based
on a high PDRI score and it should be used as a tool to esti-
mate outcome [13]. The authors also suggest that factors as
recipient selection and experience with pancreas transplanta-
tion should be included in the consideration to accept a donor
pancreas for transplantation.
P-PASS has been evaluated to predict pancreas graft sur-
vival in different countries. In a study from Poland, P-PASS
was a significant risk factor for 1-year pancreas graft survival;
patients with a functioning graft received pancreata from do-
nors with lower P-PASS. A small, but significant, difference
in P-PASS was seen; 15.7 versus 16.4 (p < 0.03) [15]. In an-
other study, a significant association between P-PASS > 17
and graft failure was only shown within 1 month after trans-
plantation (p = 0.025); at 1, 5, and 10 years, this association
was no longer demonstrated [16]. In a study from the
Netherlands, no predictive value of P-PASS could be demon-
strated [17].
No predictive value of PDRI on 1- and 5-year graft survival
was observed in two studies [15, 18]. In a large UK cohort,
PDRI was significantly associated with 1-year graft survival
in simultaneous pancreas-kidneys (SPK) recipients; however,
the survival difference between the groups with the highest
and lowest risk was only 7% at 5 years after transplantation.
One-year graft survival was higher in SPK recipients (88%)
compared with pancreas transplant alone (PTA) and pancreas
after kidney (PAK) recipients (77%) when they received a
pancreas from donors with elevated PDRI (1.57–2.21) [19].
PDRI was found to be a significant predictor of pancreas graft
survival in a Dutch study; however, also good results could be
achieved with grafts from high-PDRI donors [17]. We there-
fore conclude that the strict use of donor selection tools has
limited clinical value and might even lead to refusal of poten-
tially transplantable pancreata. The characteristics of P-PASS
and PDRI are summarized in Table 1.
Mechanism of Injury in DCD
In DCD, organs are subjected to a period of warm ischemia,
which is thought to have a detrimental effect on organ quality.
However, there is no consensus when warm ischemia actually
commences and how long an organ can sustain warm ischemia
before becoming irreversibly damaged. In the USA, warm ische-
mia is defined to start after withdrawal of life support therapy
(WLST) and ends at the initiation of cold perfusion, while in
most European countries, it is defined to start after asystole in
the donor. An arterial pressure below 50 mmHg or oxygen sat-
uration below 70% is now considered to bemore physiologically
relevant than asystole, leading to the increasingly accepted con-
cept of functional warm ischemia [10•]. WLST is commonly
performed at the ICU department, and after declaration of dead
and the 5-min “no-touch” period, the donor is taken to the oper-
ation room (OR), where amidline laparotomy and cannulation of
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the aorta are performed. Warm ischemia ends at the start of the
cold flush with preservation solution via the aorta. Warm ische-
mia leads to a quick depletion of intracellular energy sources,
such as adenosine triphosphate (ATP), and accumulation of toxic
metabolites [10•, 20]. In our study on human pancreas preserva-
tion, ATP concentration inDCDpancreatawas significantly low-
er compared with DBD pancreata after a median period of 6-h
static cold storage (SCS) [21]. In a canine study on segmental
autotransplantation after different periods of warm ischemia (30,
60, 90, and 120 min) followed by 24 h of SCS in University of
Wisconsin (UW) solution, a decline in pancreas viability after
prolonged warm ischemia was reported [22]. Pancreas grafts
were considered functional when normoglycemia for at
least 5 days after transplantation was maintained or by
positive evaluation using an intravenous glucose tolerance
test 1 week after transplantation. The viability was corre-
lated to the ATP concentrations observed: the tissue con-
centration of ATP at the end of the preservation period
was predictive for post-transplant outcome. The authors
demonstrated that pancreata subjected up to 60 min of
warm ischemia followed by 24 h of SCS were still func-
tioning after transplantation [22].
Several procurement protocols are used in order to shorten
the length of warm ischemia. In some countries, it is allowed
to perform premortem cannulation of the femoral vessels to
enable the start of cold preservation directly after declaration
of death. Heparin and vasodilatative drugs are also adminis-
tered just beforeWLST in some centers [23, 24].WLSTmight
take place at the OR instead of the ICU department, resulting
in shorter warm ischemia time. These preliminary prepara-
tions are unusual in the Eurotransplant region and the UK.
Although by definition the warm ischemic period ends when
cold flush has started, biologically, the organ still suffers from
lack of oxygen. Therefore, recently, donor organ extraction time
is considered to be important as well. This period covers part of
the cold ischemia time (CIT); it starts directly after the cold flush
in the donor and ends when the organ is retrieved from the body
and kept on ice. Earlier studies reported that prolonged kidney
extraction time leads to an increase in delayed graft function
(DGF) [25] and prolonged liver extraction time seems to have
an independent effect on liver graft outcome after transplantation
[26]. To which extent, whether the duration of pancreas extrac-
tion time has an effect on pancreas graft survival has yet to be
determined. It is however evident that as all other organs, the
Table 1 Characteristics of P-PASS and PDRI
Aim of the scoring
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Pancreata with P-PASS > 17
compared with < 17 are
discarded three times more
often (p < 0.001) [11]






p < 0.03) [15]
PPAS > 17 associated
with graft failure
after 1 month
(p = 0.025), no
association at 1, 5,
and 10 years [16]
No predictive value of
P-PASS on GS [17]
Median P-PASS of organ
donors has increased to 19
[13]
Shift towards more DCDwhile
DCD is not included in
P-PASS
The model is based on
pancreas acceptance and not
outcome after
transplantation
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Stronger prediction of organ
acceptance (AUC 0.79).
PDRI is proven more
useful than P-PASS to
predict pancreas
acceptance [13]
No predictive value on
1- and 5-year GS
[15, 18]
Significant association
with 1-year GS in
SPK (HR= 1.52,
p = 0.009) [19]




p = 0.018) [16]




(p = 0.002) [17]
Despite strong association of
high PDRI donors with
decreased GS, good results
can be achieved with high
risk grafts (PDRI > 1.24)
[17]
PDRI alone cannot be used as a
strict criterion for pancreas
acceptance
BMI, body mass index; ICU, intensive care unit; AUC, area under the curve; GS, graft survival; DCD, donation after circulatory death; SPK, simulta-
neous pancreas-kidney; PAK, pancreas after kidney
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pancreas temperature during explantation is far from the desired
4 °C. It has been demonstrated that the core pancreas temperature
rises to 16.5 °C during procurement, after an initial decline to
6.8 °C just after the cold flush. In an experimental group, in
which additional ice slush was added around the pancreas, the
core pancreas temperature remained 9 °C. Results after islet iso-
lation in both groups showed improved outcome in the experi-
mental group regarding to islet equivalent (IEQ), viability, and
response to glucose [27]. The effect of the extraction time or
pancreatic temperature on the outcome of solid organ pancreas
transplantations is currently unknown, but given the vulnerability
of the organ and the impact on other organs, it is likely that
extraction time is a relevant risk factor.
In 2015, recommendations from a European expert group
concerning DCD pancreas transplantation have been published.
Maastricht Class III and IV donors can be reasonably used for
vascularized pancreas transplantation, if warm ischemia is limit-
ed with a maximum of 30 min. A rapid retrieval technique with
perfusion of the abdominal organs should be performed via an
aortic cannula. During procurement, ice slush should be added
into the lesser sac to ensure topical cooling of the pancreas.
Preservation should be performed by static cold storage and
preservation time should be minimized.
Outcome of DCD Pancreas Transplantation
Only a few countriesworldwide have usedDCD for vascularized
pancreas transplantation: the USA, Canada, Australia, the UK,
the Netherlands, Belgium, Sweden, and Japan. Subsequently,
only a few studies reporting outcome after DCD transplantation
have been published so far. In 2016, a meta-analysis on all com-
parative cohort studies reporting the outcome after DCD and
DBD pancreas transplantation was published by our group
[28••]. It was concluded that 1-year pancreas graft survival for
SPK transplantation did not differ between DBD and DCD. Two
of the included studies reported equal long-term results after
DCD and DBD pancreas transplants (3- and 10-year patient
and graft survival). DCD pancreas recipients were howevermore
prone to develop thrombosis resulting in a higher reoperation
rate. Interestingly, this did not lead to a lower patient or graft
survival. Different definitions of warm ischemia time (WIT)
were used, so no overall median WIT could be calculated.
Despite varied lengths of WIT, even up to 110 min, all studies
described excellent graft survival rates after 1 year. In 2017, a
systematic review on DCD pancreas transplantation was pub-
lished with equal results regarding to outcome after transplanta-
tion. In a subanalysis, WIT and thrombosis rate were compared
in studies which used premortem preparations versus studies in
which these were not performed. Early femoral cannulation sig-
nificantly reduced warm ischemia time with approximately
10 min, which is, however, not yet directly associated with graft
failure. DCD pancreata were proven to have a significantly
higher rate of thrombosis than DBD pancreata. In a subgroup
analysis, this was not shown for DCD pancreata procured from
donorswhere premortem heparin administrationwas used [29••].
Recently, three papers on the outcome of DCD compared
with DBD pancreas transplantation have been published.
They all described single-center experiences including small
number of patients (DCD groups 10–21 patients and DBD
groups 68–596 patients) with a median follow up between 1
and 2.7 years. Two studies reported comparable WIT lengths
(30 and 31 min) [30, 31] while in the third center, WLSTwas
performed at the theater or nearby, leading to short WIT (data
not given) [32]. Median donor age in DCD did not differ from
DBD donors in two studies: 32 year [30] and 21 year [32],
while in the third study, DCD donors were significantly youn-
ger than DBD donors: 27 vs. 43 years (p = 0.003) [31].
Excellent graft survival was reported in all studies: 100% after
1 year [31, 32] and even still 100% after 6 years [30]. None of
the studies reported complete thrombosis leading to graft fail-
ure after DCD transplantation. Kopp and colleagues reported
an equal PDRI score in both DBD and DCD pancreas donors,
however, after eliminating the DCD factor, PDRI in this group
was significantly lower: 0.97 versus 1.61 in DCD and DBD
respectively. As indicated in this study, good results can be
achieved by transplanting DCD pancreata, if careful donor
selection is performed [31]. When it comes to risk factors
and predicting outcome after pancreas transplantation, it ap-
pears that DCD seems to play a less important role than ini-
tially thought and could therefore be considered to be a justi-
fied source of donor pancreata.
Pancreas Preservation
Nowadays, protocols for DCD pancreas preservation are quite
similar to DBD protocols and are based on the principle of
reducing cellular metabolism by lowering the temperature of
the organ by SCS. With every 10 °C drop in temperature,
cellular metabolism decreases two- to threefold, thereby lead-
ing to reduced oxygen and ATP use and reduction of ischemic
injury [33]. However, at 4 °C, 10% of metabolism is still
maintained, resulting in depletion of ATP levels in the absence
of oxygen [34]. Together with the rapid decline of energy
sources during the warm ischemic period in DCD organs, this
period can further lead to a cellular “oxygen debt,” which
results in the production of radical oxygen species and in-
creased injury during reperfusion [20, 35].
Preservation solutions have been developed to counteract
ischemic injury [36]. These act mostly by reducing cellular
swelling and maintaining pH balance and in some solutions
oxygen-free-radical scavengers and precursors for ATP are
added. Studies have shown that preservation with either
UW, Histidine-Tryptophan-Ketoglutarate (HTK), Celsior
and Institute Georgez Lopez-1 (IGL-1) did not show superi-
ority over another [37]. Currently, no studies have been per-
formed that analyzed the effect of different preservation
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solutions on DCD pancreas transplants. Given the differences
in injury during DBD and DCD procedures, it is likely to
accept that different treatments for these organs might be nec-
essary [36]. Multiple techniques have been developed and
tested in order to reduce ischemia-reperfusion injury after
transplantation. These techniques are most of all focused on
maintaining cellular ATP by delivery of high oxygen concen-
trations to the tissue. The most explored techniques for pan-
creas preservation will be explained further.
Two-Layer Method
In 1988, the two-layer method (TLM) was developed by a
Japanese group with the intention to improve pancreas viabil-
ity during preservation for islet isolation. This technique in-
volves the addition of perfluorocarbon (PFC) to the preserva-
tion solution, in order to combine the characteristics of the
preservation solution and PFC together to prevent injury and
supply oxygen during preservation. PFC is an inert solution
with a high capacity for dissolving oxygen [34]. By addition
of PFC to a preservation fluid, two layers are formedwith PFC
at the bottom and the preservation solution on top. The organ
is placed in the solution which is presaturated with oxygen or
continuously oxygenated during preservation. Oxygen is de-
livered to the pancreas by passive diffusion, with the intention
to achieve ATP production in the presence of precursors in the
preservation solution [36, 37]. Experimental studies in small
animals showed promising results of TLM regarding to ATP
levels when compared with SCS [38]. The ability of oxygen to
penetrate deep in the tissue of large animals and humans is
however questioned. In porcine pancreata preserved by the
TLM, ATP levels were nearly undetectable and indistinguish-
able from those preserved by SCS alone [39]. In a large retro-
spective study from Sweden, the outcome of 200 islet isola-
tions from human pancreata was analyzed, from which 103
pancreata were preserved by TLM and 97 pancreata by SCS.
No differences with regard to islet yield, purity, or dynamic
glucose stimulation after islet isolation was demonstrated.
Islet post-transplant function in recipients was also equal in
both groups. Subgroup analysis showed that TLM did not
improve outcome either after prolonged CIT or in elderly do-
nors (> 60 years of age) [40]. Recently, no studies on TLM of
the pancreas have been published and as far as we know, TLM
is not routinely used for pancreas preservation.
Persufflation
In organ persufflation, humidified and filtered oxygen is bub-
bled directly to an organ via its vasculature. Oxygen
persufflation can either be performed anterograde (through
the arteries) or retrograde (through the portal vein). The tech-
nique was first discovered coincidentally in 1902 when com-
pressed oxygen instead of blood was perfused through a feline
heart, leading to continuation of heart contractility [41]. In the
last decades, the beneficial effects of this technique have been
analyzed in experimental settings in the heart, kidneys, and
livers. It has been shown that with this relatively simple tech-
nique, oxygen could be delivered to organs during cold stor-
age, whereby ATP levels could be replenished and maintained
with associated reduction of oxidative stress and lipid perox-
idation [42–45]. Research concerning pancreas persufflation
has been focused on pancreas preservation for islet transplan-
tation. Scott et al. reported in their study on anterograde
persufflation of DBD human and DCD porcine pancreata via
the splenic artery and celiac trunk that oxygen was uniformly
distributed throughout the organ and ATP concentration was
restored [38]. Persufflation dramatically improved tissue
health as shown by distended capillaries and significantly less
autolysis and cell death when compared with TLM [39]. In a
rat model, portal venous persufflation of the pancreas has
shown to be superior to SCS and HMP regarding outcome
of islet isolation [46]. In a recent study on human pancreata,
a lowered expression of inflammatory genes in isolated islets
after persufflation compared with SCS was reported.
Preservation time could be extended with persufflation with-
out additional loss of islet function or viability [47]. This tech-
nique is promising for pancreas preservation, as it allows the
delivery of oxygen properly to the pancreatic tissue, without
major complications. However, no research has yet been per-
formed on its use in pancreas preservation for solid organ
transplantation.
Machine Perfusion
Hypothermic machine perfusion (HMP) is a technique which
enables continuous circulation of the microvasculature with
cold preservation solution, removing toxic metabolites and
supporting ATP synthesis by delivery of oxygen and adeno-
sine [36]. HMP has been evaluated in donor organ preserva-
tion for different reasons; to improve the quality of marginal
donor organs, to extend the preservation time, and to test graft
viability. Previous clinical studies in kidneys showed especial-
ly beneficial effects of HMP on graft function after DCD or
ECD kidney transplantation [48], and this technique is nowa-
days standard of care in some countries, among which is the
Netherlands. In experimental and clinical studies on human
DCD livers, excellent results were reported after oxygenated
HMP with a restoration of ATP and improved hepatobiliary
function [49] and a 100% graft survival 6 months after trans-
plantation [20].
Early studies on HMP of canine pancreata concluded that
pancreas storage time could be extended up to 24 h, while
retaining viability [50] and function of isolated islets after
autotransplantation in dogs [51]. Another study reported that
tissue flow rate during HMP was a predictable index of pan-
creatic graft viability [52]. There has always been a hesitation
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to HMP of the pancreas, because it is a low-flow organ with a
delicate vasculature and HMP is associated with edema and
congestion with the risk of thrombosis [36, 53]. Because HMP
of the pancreas is relatively complex and results of SCS have
improved after development of dedicated perfusion solution,
HMP fell out of favor. Lately, however, there is renewed in-
terest in HMP of the pancreas, mainly because the lack of
good-quality pancreas donors forces the search to improve
the quality of marginal donor pancreata. During the last
15 years, few studies on HMP of the pancreas have been
reported.Most of them involved animal pancreata and focused
on pancreas preservation for islet isolation. Twenty-four hours
of HMP of porcine pancreata led to moderate edema without
loss of function of the isolated islets. The edema seemed to aid
in enzymatic digestion, leading to a higher islet yield and
purity of isolated islets compared with 24 h of SCS [54, 55].
In a split lobe porcine model, the results of islet transplantation
in diabetic mice after 24-h HMP were analyzed. All mice
receiving islets fromHMP preserved pancreata showed recov-
ery in diabetes and high viability as measured by oxygen
consumption [56]. A protective effect on graft histopathology
by 6-h HMP was reported in DCD porcine pancreata [57].
In the first study on human pancreata, four human donor
pancreata were perfused for 4 h by HMP after 13 h of SCS,
resulting in an adequate amount of islets that could be isolated
with excellent in vitro viability [58]. In a recent study per-
formed by our team, 20 human pancreata were included, from
which 10 (5 DCD and 5 DBD) were subjected to 6-h HMP
and 10 (5 DCD and 5 DBD) to 6-h of additional SCS after a
median period of 6-h SCS. Oxygenated HMP with 25 mmHg
was performed via the splenic and mesenteric artery separate-
ly. Uniform perfusion of the pancreata as shown by fluores-
cence microscopy was obtained and perfusion flow increased
during the first minutes of HMP before it stabilized. ATP
concentration increased significantly after HMP in both
DCD and DBD organs with a respectively 6.8-fold and 2.6-
fold increase. Also, ATP concentration of DCD pancreata was
significantly lower at the start of HMP (8.4 in DCD and
48.2 μmol/g protein in DBD), which corrected after HMP to
equal ATP concentrations (100.5 in DCD and 109.3 μmol/g
protein in DBD). HMP did not induce cellular injury or ede-
ma. In two DCD pancreata, islet isolation was performed with
good viability and in vitro function [21]. Another study dem-
onstrated that 24 h of HMP with a perfusion pressure of
25 mmHg did not lead to macroscopic edema on human
pancreata as conformed by histological analysis. After 12 h
of HMP, insulin, glucagon, and somatostatin staining were
normal [35]. This evidence suggests that HMP of the human
pancreas is a safe preservation method regarding tissue injury
and edema formation and replenishment of ATP can be
achieved. However, the main limitation of these studies is
the lack of a post-transplant evaluation reperfusion model in
a normothermic environment.
Normothermic machine perfusion (NMP) can be used to
improve organ quality during preservation and facilitate the
administration of drugs, and it allows viability testing in a
physiological environment prior to transplantation [59]. In
experimental settings, it has been successfully used for viabil-
ity testing in human donor livers [60] and kidneys [61].
Viability assessment of porcine pancreata was performed
using NMP, to examine the effect of 5-h HMP compared with
SCS alone after a prolonged period of 24-h CIT [53]. During
HMP, perfusion flow was stable and the grafts experienced a
weight gain of 15.3–27.6%. Perfusion flow indices (PFI)
remained stable during normothermic reperfusion in the
pancreata that were attributed to HMP, whereas the SCS-
only pancreata showed declined PFI during reperfusion. In
the second part of the study, three discarded human pancreata
were perfused by HMP after prolonged period of CIT (up to
56 h). Stable PFI was shown with only mild weight gain
(3.9% and 14.7%). Functional assessment during NMP dem-
onstrated beta-cell viability in these grafts, even after
prolonged period of SCS [53]. In a study on five discarded
human pancreata, 1–2 h of NMP was performed for viability
assessment after a median CIT of 13 h. One pancreas with a
CIT of over 30 h was excluded from the analysis, given the
macroscopically ischemic appearance of the duodenum and
therefore poor comparability to the other organs according to
the authors. In the included four pancreas grafts, stable mean
arterial flow was maintained during NMP, and insulin secre-
tion was observed in all pancreata although tissue edema did
occur in all grafts [59]. In a study evaluating NMP as a pres-
ervation, 2-h NMP was performed in four DCD porcine
pancreata after a short WIT (8.3 ± 6.6 min) and CIT (34 ±
7.8 min). All pancreata became moderately to severely edem-
atous, congested, and hemorrhagic during NMP. Extensive
hemolysis occurred and the pancreas looked grossly ischemic
at the end of preservation [62]. As these studies give an insight
in the possibility of NMP for assessing pancreas viability, the
technique should be further optimized to avoid hemolysis and
edema.
Conclusion
Despite a growing incidence in type 1 DM, pancreas trans-
plantation rates are declining worldwide. As beta-cell replace-
ment is the best therapeutic option for these patients, better
assessment of possible pancreas donors is needed to expand
the donor pool without compromising the outcome. This over-
view shows that excellent results can be achieved with DCD
pancreas transplantation, when other detrimental donor char-
acteristics are kept to a minimum. Donor selection tools are
developed in order to assess potential pancreas donors. PDRI
did show to have a predictive value in outcome; however,
conflicting cutoff points have been found in different studies.
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PDRI can be used as a tool to estimate the risk of a certain
donor pancreas; nevertheless, other transplant and recipient
factors should be kept in consideration. DCD should not be
the sole reason to decline a pancreas for transplantation,
though accumulation of risk factors in these donors should
be avoided. Hypothermic oxygenated machine perfusion
seems a promising preservation method for these organs, as
it safely replenishes ATP concentrations.
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